Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: May 26, 2026

A Quick and Efficient Method for the Purification of Endoderm Cells Generated from Human Embryonic Stem Cells
08:34

A Quick and Efficient Method for the Purification of Endoderm Cells Generated from Human Embryonic Stem Cells

Published on: March 3, 2016

Optimizing stem cell collection through CXCR4 antagonists.

Hemchandra Mahaseth1, Jonathan Kaufman

  • 1Winship Cancer Institute, Emory University, Atlanta, GA, USA. hmahase@emory.edu

Frontiers in Bioscience (Scholar Edition)
|December 29, 2011
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

CRESTONE: A Phase II Study of the Efficacy and Safety of the HER3 Monoclonal Antibody, Seribantumab, in Solid Tumors With Neuregulin-1 (<i>NRG1</i>) Fusions.

JCO precision oncology·2025
Same author

Unraveling the complexity of bladder-centric chronic pain by intravesical contrast enhanced MRI.

Continence (Amsterdam, Netherlands)·2025
Same author

Correction: Treating Lower Urinary Tract Symptoms in Older Adults: Intravesical Options.

Drugs & aging·2024
Same author

Enhancing Therapeutic Efficacy and Safety of Immune Checkpoint Inhibition for Bladder Cancer: A Comparative Analysis of Injectable vs. Intravesical Administration.

International journal of molecular sciences·2024
Same author

Treating Lower Urinary Tract Symptoms in Older Adults: Intravesical Options.

Drugs & aging·2023
Same author

Nanophotonic control of thermal emission under extreme temperatures in air.

Nature nanotechnology·2022

Plerixafor, a CXCR4 antagonist, effectively mobilizes hematopoietic stem cells. This approach, combined with G-CSF, improves stem cell collection for transplantation, overcoming limitations of G-CSF alone.

Area of Science:

  • Hematology
  • Oncology
  • Pharmacology

Background:

  • Peripheral blood stem cells are crucial for autologous and allogeneic transplantation.
  • Standard mobilization with G-CSF or chemotherapy recovery fails in 5-30% of patients.
  • Inadequate stem cell collection limits high-dose chemotherapy efficacy.

Purpose of the Study:

  • To review the development of plerixafor as a stem cell mobilizer.
  • To outline optimal strategies for peripheral blood stem cell collection.
  • To highlight plerixafor's role in overcoming mobilization challenges.

Main Methods:

  • Review of clinical trials and scientific literature on plerixafor.
  • Analysis of plerixafor's mechanism of action as a CXCR4 antagonist.

More Related Videos

Evaluation of Abnormal Growth-related Genes of Hematopoietic Stem and Progenitor Cells by Combining CRISPR/Cas9 Technology with Cell Counting
07:01

Evaluation of Abnormal Growth-related Genes of Hematopoietic Stem and Progenitor Cells by Combining CRISPR/Cas9 Technology with Cell Counting

Published on: May 2, 2025

CRISPR/Cas9 Gene Editing of Hematopoietic Stem and Progenitor Cells for Gene Therapy Applications
08:32

CRISPR/Cas9 Gene Editing of Hematopoietic Stem and Progenitor Cells for Gene Therapy Applications

Published on: August 9, 2022

Related Experiment Videos

Last Updated: May 26, 2026

A Quick and Efficient Method for the Purification of Endoderm Cells Generated from Human Embryonic Stem Cells
08:34

A Quick and Efficient Method for the Purification of Endoderm Cells Generated from Human Embryonic Stem Cells

Published on: March 3, 2016

Evaluation of Abnormal Growth-related Genes of Hematopoietic Stem and Progenitor Cells by Combining CRISPR/Cas9 Technology with Cell Counting
07:01

Evaluation of Abnormal Growth-related Genes of Hematopoietic Stem and Progenitor Cells by Combining CRISPR/Cas9 Technology with Cell Counting

Published on: May 2, 2025

CRISPR/Cas9 Gene Editing of Hematopoietic Stem and Progenitor Cells for Gene Therapy Applications
08:32

CRISPR/Cas9 Gene Editing of Hematopoietic Stem and Progenitor Cells for Gene Therapy Applications

Published on: August 9, 2022

  • Evaluation of plerixafor's efficacy in combination with G-CSF.

    • Main Results:

    • Plerixafor is a potent stem cell mobilizer.
    • Plerixafor plus G-CSF demonstrates superiority over G-CSF alone in clinical trials.
    • This combination led to FDA approval for specific hematologic malignancies.

    Conclusions:

    • Plerixafor represents a significant advancement in stem cell mobilization.
    • Optimal strategies involving plerixafor enhance stem cell collection success rates.
    • This improves treatment options for patients undergoing high-dose chemotherapy and stem cell transplantation.